Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 6:13:965535.
doi: 10.3389/fphar.2022.965535. eCollection 2022.

Online survey of medicinal cannabis users: Qualitative analysis of patient-level data

Affiliations

Online survey of medicinal cannabis users: Qualitative analysis of patient-level data

Albert Garcia-Romeu et al. Front Pharmacol. .

Abstract

Aim: To characterize perceived benefits and challenges experienced by medicinal cannabis users. Methods: An anonymous online survey collected demographics, health information, and open-ended responses from medicinal cannabis users regarding perceptions, motivations, and experience of treatment. Qualitative open-ended responses were thematically analyzed. Results: Respondents (N = 808) were predominantly White (79%), female (63%), with a mean (SD) age of 38 (20). Two hundred eighty-four (35%) respondents provided data on a dependent family member (e.g., child; 22% of total sample). Most used cannabidiol (CBD)-dominant products (58%), primarily for neurological disorders (38%) or pain (25%). Primary motivations for medicinal cannabis use were based on beliefs that traditional treatments were ineffective and/or had intolerable side effects (51%), positive scientific or media portrayals of the safety/efficacy of cannabis as a therapeutic (29%), or preference for "natural" treatments over pharmaceuticals (21%). A majority of respondents (77%) attributed positive effects to the medicinal use of cannabis/cannabinoids. These included physical symptom improvements such as reduced pain (28%), improved sleep (18%), and seizure reduction (18%), and mental health improvements including reduced anxiety (22%) and improved mood (11%). Additionally, respondents reported reduced use of other medications (e.g., opioids) (12%), and improved quality of life (14%). Problems associated with use were cited by 41% of respondents, and included unwanted side effects (16%), lack of information or medical support (16%), prohibitive costs (12%), and legal concerns (10%). Conclusion: Most participants reported benefits from cannabis use for a variety of conditions where traditional treatments were ineffective or unacceptable. Concerns regarding cannabis side effects, legality, lack of information, and cost were raised. Data indicate greater research and education on the safety and efficacy of medicinal cannabis/cannabinoid use is warranted.

Keywords: CBD-cannabidiol; THC-tetrahydrocannabinol; cannabis (marijuana); medical marijuana; qualitative.

PubMed Disclaimer

Conflict of interest statement

AG-R is a scientific advisor to Etha Natural Botanicals, Innerwell, and NeonMind Biosciences. RV has received compensation as a consultant or scientific advisor from MyMD Pharmaceuticals, Mira1a Pharmaceuticals Inc. Canopy Health Innovations, Syqe Medical Ltd. WebMD, and Radicle Science Inc. MB-M is employed by Canopy Growth Corporation. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

Cited by

References

    1. Bachhuber M., Arnsten J. H., Wurm G. (2019). Use of cannabis to relieve pain and promote sleep by customers at an adult use dispensary. J. Psychoact. Drugs 51 (5), 400–404. 10.1080/02791072.2019.1626953 - DOI - PMC - PubMed
    1. Benyamin R., Trescot A. M., Datta S., Buenaventura R., Adlaka R., Sehgal N., et al. (2008). Opioid complications and side effects. Pain Physician 11, S105–S120. 10.36076/ppj.2008/11/s105 - DOI - PubMed
    1. Black N., Stockings E., Campbell G., Tran L. T., Zagic D., Hall W. D., et al. (2019). Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet. Psychiatry 6 (12), 995–1010. 10.1016/S2215-0366(19)30401-8 - DOI - PMC - PubMed
    1. Bonn-Miller M. O., Pollack C. V., Casarett D., Dart R., ElSohly M., Good L., et al. (2019). Priority considerations for medicinal cannabis-related research. Cannabis Cannabinoid Res. 4 (3), 139–157. 10.1089/can.2019.0045 - DOI - PMC - PubMed
    1. Bonn-Miller M. O., Brunstetter M., Simonian A., Loflin M. J., Vandrey R., Babson K. A., et al. (2022). The long-term, prospective, therapeutic impact of cannabis on post-traumatic stress disorder. Cannabis Cannabinoid Res. 7 (2), 214–223. 10.1089/can.2020.0056 - DOI - PMC - PubMed

LinkOut - more resources